Literature DB >> 19817326

Ovarian cancer: an overview.

Michelle A Roett1, Patricia Evans.   

Abstract

Although ovarian cancer may occur at any age, it is more common in patients older than 50 years. Patients often present with nonspecific pelvic or abdominal symptoms. Initial diagnostic tests include transvaginal ultrasonography and serum cancer antigen 125 measurement; however, these tests are not specific for ovarian cancer. Conventional treatment includes surgical debulking followed by chemotherapy. Prognosis is typically determined by the cancer stage and grade, although future treatment may depend on tumor genetic composition. Epithelial ovarian cancer is the most common type of ovarian cancer, and because 70 percent of cases are diagnosed at stage III or IV, it is associated with a poor prognosis. Preventive visits provide an opportunity to identify and educate women at increased risk of ovarian cancer, but routine screening is not recommended. Women with a family history of ovarian cancer or a known associated genetic syndrome should be offered genetic counseling or a discussion of available preventive interventions, respectively.

Entities:  

Mesh:

Year:  2009        PMID: 19817326

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  64 in total

1.  Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort.

Authors:  Alison J Canchola; Ellen T Chang; Leslie Bernstein; Joan A Largent; Peggy Reynolds; Dennis Deapen; Katherine D Henderson; Giske Ursin; Pamela L Horn-Ross
Journal:  Cancer Causes Control       Date:  2010-10-06       Impact factor: 2.506

2.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Anette Kjaerbye-Thygesen; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

Review 3.  Salpingectomy as a means to reduce ovarian cancer risk.

Authors:  Mary B Daly; Charles W Dresher; Melinda S Yates; Joanne M Jeter; Beth Y Karlan; David S Alberts; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-13

4.  Evaluation of microsatellite instability in women with epithelial ovarian cancer.

Authors:  Leonardo Pandolfi Caliman; Rubens Lene Carvalho Tavares; Josiane Barbosa Piedade; Ana Carolina Silvano Couto DE Assis; Karen DE Jesus Dias DA Cunha; Letícia DA Conceição Braga; Luciana Maria Silva; Agnaldo Lopes DA Silva Filho
Journal:  Oncol Lett       Date:  2012-06-27       Impact factor: 2.967

5.  Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.

Authors:  Acharaporn Duangjai; Kui Luo; Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2013-12-04       Impact factor: 5.571

6.  Ovarian Cancer Stem Cells: Characterization and Role in Tumorigenesis.

Authors:  Sarama Saha; Seema Parte; Partha Roy; Sham S Kakar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer.

Authors:  Yajuan Su; Lei Zheng; Qian Wang; Weiqi Li; Zhen Cai; Shilong Xiong; Jie Bao
Journal:  J Exp Clin Cancer Res       Date:  2010-03-24

8.  Long noncoding RNA DUXAP8 regulates proliferation and apoptosis of ovarian cancer cells via targeting miR-590-5p.

Authors:  Qingyou Meng; Zhongliang Li; Jiaxue Pan; Xiaorong Sun
Journal:  Hum Cell       Date:  2020-08-04       Impact factor: 4.174

9.  Thrombomodulin mediates the progression of epithelial ovarian cancer cells.

Authors:  Lu-Min Chen; Weu Wang; Jen-Chih Lee; Feng-Hsiang Chiu; Chun-Te Wu; Cheng-Jeng Tai; Chien-Kai Wang; Chen-Jei Tai; Ming-Te Huang; Yu-Jia Chang
Journal:  Tumour Biol       Date:  2013-08-06

10.  The added value of circulating tumor cells examination in ovarian cancer staging.

Authors:  Katarina Kolostova; Rafał Matkowski; Marcin Jędryka; Katarzyna Soter; Martin Cegan; Michael Pinkas; Anna Jakabova; Jiri Pavlasek; Jan Spicka; Vladimir Bobek
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.